Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CARB-X funds new gonorrhea treatment work
September 2018
SHARING OPTIONS:

OXFORD, U.K. & CAMBRIDGE, Mass.—Summit Therapeutics plc recently received a grant of up to $4.5 million from the public-private partnership CARB-X to support Summit’s lead series of new mechanism antibiotic compounds for gonorrhea. Initially, Summit will receive $2 million in funding to support the selection of a preclinical candidate, which is expected in H2 2018. The other $2.5 million is divided into two option segments, which CARB-X can exercise if certain development milestones are reached.
 
“Drug-resistant gonorrhea is an urgent and growing public health problem around the world, affecting the health and quality of life of millions of people,” said Kevin Outterson, CARB-X’s executive director. “The world urgently needs new antibiotics, like those that Summit is developing, and other lifesaving products to protect us from drug-resistant bacteria.  The projects in the Powered by CARB-X portfolio are in the early stages of development, but if successful, they offer tremendous potential in the fight against superbugs.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.